Alvotech to Report Financial Results for H1 2026
Rhea-AI Summary
Alvotech (NASDAQ: ALVO; ALVO-SDB) will release its financial results for the first half of 2026 on Wednesday, August 19, 2026, after the U.S. market close.
The company will host a webcast with live Q&A on Thursday, August 20, 2026, at 08:00 ET (12:00 GMT, 13:00 BST, 14:00 CEST). Registration links are provided for both the webcast and Q&A, and presentation materials will be available on alvotech.com/financials before the call.
Positive
- None.
Negative
- None.
Market Reaction – ALVO
Following this news, ALVO has declined 0.79%, reflecting a mild negative market reaction. Our momentum scanner has triggered 2 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $3.78.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 24 | Q1 earnings date | Neutral | +0.0% | Scheduled first-quarter results release and webcast with live Q&A |
| Mar 04 | FY earnings date | Neutral | +2.4% | Scheduled fourth-quarter and full-year results release with conference call |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Tag-specific earnings-date notices produced mixed prior reactions, ranging from 0% to +2.37%, rather than a consistent direction.
Key Terms
biosimilar medicines medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
REYKJAVIK, ICELAND (August 10, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will release its financial results for the first half of 2026 on Wednesday, August 19, 2026, after the U.S. market close.
The Company will also host a webcast with a live Q&A on Thursday, August 20, 2026, at 08:00 ET (12:00 GMT, 13:00 BST, 14:00 CEST).
- To listen to the webcast, please register here: H1 2026 webcast
- To participate in the Q&A, please register here: Q&A registration
Slides and other materials will be made available on alvotech.com/financials before the call.
For further information, contact:
Media
Benedikt Stefansson
Sarah MacLeod
alvotech.media@alvotech.com
Investors
Dr. Balaji V Prasad (US)
Benedikt Stefansson (IS)
alvotech.ir@alvotech.com
About Alvotech
Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China and other Asian countries, and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com.
For more information, please visit our website or follow us on social media on LinkedIn, Facebook, Instagram and YouTube.
None of the information on the Alvotech website shall be deemed part of this press release.
